Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Status:
RECRUITING
Trial end date:
2027-04-25
Target enrollment:
Participant gender:
Summary
This study aims to evaluate whether maintenance therapy with decitabine, venetoclax and blinatumomab could improve the 2-year progression free survival (PFS) of patients with philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who had recently received an allogeneic stem cell transplant and in measurable residual disease-negative remission.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University